Coronary Artery Disease (CAD): Understanding Atherosclerotic Heart Disease

Understanding risk early. Preventing events before they occur.

CAD / ASCVD Overview

A common, progressive cardiometabolic condition — and the leading cause of cardiovascular events worldwide.

 What Is CAD / Atherosclerosis?

  • Atherosclerosis is a chronic process of plaque buildup within arterial walls
  • These plaques are composed of cholesterol, inflammatory cells, and fibrous tissue
  • Over time, this leads to:
      • Narrowing of arteries (stenosis)
      • Reduced blood flow
      • Plaque rupture → clot formation → acute events (heart attack or stroke) 

Coronary artery disease (CAD) refers specifically to atherosclerosis affecting the heart’s arteries.

Often silent — until it presents as a life-changing event.

   Why Does It Matter?

Atherosclerosis is the underlying driver of:

  • Heart attack (myocardial infarction)
  • Angina (chest pain due to reduced blood flow)
  • Stroke (when affecting cerebral circulation)
  • Peripheral artery disease (PAD)
  • Sudden cardiac death

Events often occur abruptly — but the disease often begins silently early in life and progresses over decades.

Impact & Epidemiology

Widespread. Unevenly distributed. Influenced by both biology and environment.

CAD: Global & U.S. Impact

  • Cardiovascular disease is the leading cause of death globally
  • Coronary artery disease (CAD) is the most common form of cardiovascular disease
  • In the U.S., a heart attack occurs approximately every 40 seconds
  • Nearly 1 in 5 deaths are due to cardiovascular disease

 

High burden. Often preventable. Frequently delayed recognition.

Who Is Most Affected?

Prevalence varies across populations:

  • Higher and earlier risk in South Asians
  • Higher risk in men at younger ages; risk increases in women after menopause
  • Differences across racial and ethnic groups influenced by social, metabolic, and access-related factors

South Asians often develop coronary artery disease earlier — even at lower levels of traditional risk factors.

Risk Factors

Atherosclerosis is driven by a small number of core biological processes — with additional factors modifying overall risk.

Modifiable Risk Factors

 

Primary Drivers

  • Atherogenic lipoproteins (LDL cholesterol)
    • Central to plaque formation and progression
    • Cumulative exposure over time determines risk
  • Hypertension
    • Promotes endothelial injury and accelerates atherosclerosis
  • Insulin resistance and diabetes
    • Drives inflammation, dyslipidemia, and vascular dysfunction
  • Smoking and tobacco exposure
    • Potent, independent risk factor
    • Promotes both plaque progression and thrombosis

 

Amplifiers of Risk

  • Obesity, particularly visceral (central) adiposity
  • Physical inactivity- sedantary lifestyle
  • Dietary patterns high in refined and ultra-processed foods
  • Metabolic dysfunction (including fatty liver/MASLD)
  • Chronic stress and poor sleep

These factors often cluster and act synergistically, amplifying underlying risk.

Non-Modifiable Risk Factors

  • Age
  • Sex (earlier risk in men; increasing risk in women after menopause)
  • Family history of premature coronary artery disease
  • Ethnicity (including higher and earlier risk in South Asians)

Risk from these factors may not be modifiable— but progression can be influenced.

Risk Enhancers (Selected Clinical Contexts)

  • Elevated lipoprotein(a) [Lp(a)]
  • Chronic inflammatory conditions
  • Chronic kidney disease
  • Obstructive sleep apnea

Risk is cumulative — driven by long-term exposure to these factors rather than any single measurement.

Symptoms of CAD

A predominantly silent condition — often asymptomatic

 Symptoms When Present

CAD is often silent until advanced or until an acute event occurs. 

When symptoms occur, they may include:

  • Chest pain or pressure (angina)
  • Discomfort radiating to arm, jaw, neck, or back
  • Shortness of breath
  • Fatigue (especially with exertion)
  • Sweating (often sudden or unexplained)
  • Nausea or lightheadedness

Disease Progression & Clinical Spectrum

  • Early stage
    Plaque buildup within the arterial wall without symptoms
  • Stable CAD
    Fixed narrowing of the artery → predictable symptoms with exertion (stable angina)
  • Unstable plaque
    Plaque disruption or rupture → sudden reduction in blood flow to the heart muscle

  • Acute coronary syndrome (ACS)
    A spectrum of acute conditions caused by plaque rupture and clot formation, including:

    • Unstable angina
      Reduced blood flow without sustained heart muscle injury
    • Myocardial infarction (heart attack)
      Prolonged or complete blockage of a coronary artery → injury to the heart muscle

 

Risk is determined not just by blockage — but by plaque stability.

Glowing red heart with radiating rays

Recognizing an Emergency

 

Time is muscle.

 

Delays in treatment can lead to irreversible heart damage.

If symptoms suggest a heart attack:

Call 911 immediately

Do not delay or attempt to drive yourself

 

Symptoms may be subtle — especially in women and diabetics.

Complications of Coronary Artery Disease

Progressive atherosclerosis can lead to both acute events and chronic cardiac dysfunction.

Common Complications

  • Myocardial infarction (heart attack)
    Acute vessel blockage leading to heart muscle injury
  • Heart failure
    Resulting from prior infarction or chronic ischemia
  • Arrhythmias
    Including atrial fibrillation and ventricular arrhythmias
  • Sudden cardiac death
    Often due to malignant arrhythmias
  • Chronic angina and functional limitation
    Reduced exercise tolerance and quality of life

 

Complications may arise from both progressive atherosclerosis and acute events — reinforcing the importance of early detection and timely intervention.

Assessment & Risk Stratification

Risk assessment guides the intensity of prevention and treatment decisions.

Global Risk Estimation

  • ASCVD Risk Calculator

    • Initial risk is estimated using validated risk calculators
    • 10-year ASCVD risk is estimated using pooled cohort equations in adults aged 40–75
    • Risk is categorized as:
      • Low
      • Borderline
      • Intermediate
      • High

     

    Risk estimation helps guide decisions regarding lifestyle interventions and medical therapy.

     

Factors Used in Risk Estimation

Risk calculators incorporate a combination of clinical variables, including:

  • Age and sex
  • Blood pressure
  • Cholesterol levels (total and HDL cholesterol)
  • Diabetes status
  • Smoking status

These estimates provide a starting point and are refined using additional clinical factors.

 

Risk Enhancers (When Risk Is Uncertain)

In individuals with borderline or intermediate risk, additional factors help refine decisions:

  • Family history of premature CAD
  • Elevated lipoprotein(a) [Lp(a)]
  • Chronic inflammatory conditions
  • Chronic kidney disease
  • Metabolic syndrome

These factors may shift management toward more aggressive prevention.

 

Coronary Artery Calcium (CAC) Scoring

  • CAC scoring helps further refine risk when uncertainty remains
  • A higher CAC score indicates greater atherosclerotic burden
  • A score of zero may reclassify risk lower in selected individuals

Important Population Considerations

  • Traditional risk calculators may underestimate risk in certain populations, including South Asians
  • Clinical judgment is essential when applying risk scores

Risk assessment is not a single number — it integrates clinical judgment, risk factors, and individual context.

Management of CAD / ASCVD Risk

Risk-based, individualized care — with a strong focus on prevention.

Chronic Preventive Management

Lifestyle Foundations

  • Heart-healthy nutrition pattern
  • Regular physical activity (aerobic + resistance)
  • Weight optimization and visceral fat reduction
  • Sleep and stress regulation
  • Tobacco avoidance

 

Lifestyle interventions remain first-line therapy for cardiovascular risk reduction.

Medical Therapy (When Needed)

 

  • Lipid-Lowering Therapy

    • LDL lowering is central to atherosclerotic risk reduction.
    • Statins
      • First-line therapy for LDL reduction and cardiovascular risk reduction
    • Additional lipid-lowering agents (when needed)
      • Ezetimibe or PCSK9 inhibitors for further LDL reduction in higher-risk individuals or when targets are not achieved
  • Blood Pressure Management
    • Reduces cardiovascular risk and slows disease progression
    • First-line agents
      • ACE inhibitors/ARBs, calcium channel blockers, and thiazide-type diuretics
    • Often requires combination therapy to achieve target blood pressure

  • Diabetes & Weight Management

    • Glycemic and weight management
      • Essential for reducing cardiovascular risk and improving metabolic health
    • Pharmacologic therapies
      • Include agents such as GLP-1 receptor agonists with demonstrated cardiovascular benefit in high-risk individuals

      • SGLT2 inhibitors

        • Reduce heart failure and cardiovascular outcomes in selected individuals
    • Treatment approach
      • Individualized based on metabolic profile, comorbidities, and overall cardiovascular risk

  • Antiplatelet Therapy

    • Indicated in individuals with established cardiovascular disease
      • Reduces risk of recurrent cardiovascular events
    • Primary prevention
      • Considered selectively in higher-risk individuals after assessing bleeding risk
    • Treatment approach
      • Requires individualized decision-making balancing cardiovascular benefit and bleeding risk

 

In established CAD, sustained and comprehensive management is essential to prevent recurrent events.

Monitoring & Long-Term Care

  • Periodic risk reassessment
  • Lipid and metabolic monitoring
  • Adjustment of therapy over time
  • Long-term adherence

Management of CAD begins with prevention — and prevention is not a one-time decision, but sustained longitudinal care.

Acute Management 

Acute Coronary Syndrome

  • Urgent evaluation and stabilization
    • Immediate medical assessment when acute coronary syndrome is suspected
  • Reperfusion therapy
    • Restoration of blood flow through preferably  percutaneous coronary intervention (PCI) or thrombolysis when PCI is not available.
  • Adjunctive medical therapy
    • Includes antiplatelet, anticoagulant, and early initiation of statin therapy

Prevention & Early Action

Early detection and timely action shapes long-term cardiovascular outcomes..

Know Your Risk

  • Lipids, blood pressure, glucose
  • Family history
  • Early screening in higher-risk populations

Act Early

  • Address risk factors before symptoms
  • Focus on sustainable lifestyle patterns
  • Initiate therapy when appropriate

Stay Consistent

  • Long-term adherence to healthy habits
  • Periodic reassessment and follow-up
  • Adjusting strategies over time

Small, consistent actions — sustained over time — prevent major events.

Plaque builds silently.
Events occur suddenly.
Prevention must begin early.

Back to Health Topics
Explore Health Resources
Explore Aikyaa Programs

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Please consult your physician or qualified healthcare provider for personalized guidance.

Learn more about Aikyaa’s Terms of Use and Copyright Policy →

“Aikyaa” refers to Aikyaa Heart Health & Wellness PLLC.